RxDoctor Payments Data

Saw Aye, MD

Internal Medicine · Petaluma, CANPI 1972751915

Payments from drug & device makers

$660in general payments, 2019–2025

Across 40 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$316
  • Sumitomo Pharma America, Inc.$124
  • Astellas Pharma US Inc$85
  • Sanofi-aventis U.S. LLC$72
  • Edwards Lifesciences$38
  • Novo Nordisk$25

What the payments were for

  • Speaking & faculty fees$7211%
  • Food & beverage$50376%
  • Education$8513%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$660 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$365,758
Medicare patients
897
Services billed
4,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide140$204,470
EliquisApixaban174$168,315
JardianceEmpagliflozin140$138,890
MounjaroTirzepatide84$127,114
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$70,606
XareltoRivaroxaban43$54,458
MyrbetriqMirabegron61$50,459
ProliaDenosumab24$40,990
JanuviaSitagliptin Phosphate41$37,398
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog52$36,565
TrulicityDulaglutide30$34,197
CreonLipase/Protease/Amylase17$28,271
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$27,267
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog26$26,027
Breo ElliptaFluticasone/Vilanterol41$20,431

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$25$204,470140 claims
Astellas Pharma US IncMyrbetriq$85$50,45961 claims
AbbVieCreon, Synthroid$316$36,648115 claims
Sumitomo Pharma America, Inc.Gemtesa$124$17,48816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Petaluma

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →